BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ren ZH, Lin CZ, Cao W, Yang R, Lu W, Liu ZQ, Chen YM, Yang X, Tian Z, Wang LZ, Li J, Wang X, Chen WT, Ji T, Zhang CP. CD73 is associated with poor prognosis in HNSCC. Oncotarget 2016;7:61690-702. [PMID: 27557512 DOI: 10.18632/oncotarget.11435] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Lupia M, Angiolini F, Bertalot G, Freddi S, Sachsenmeier KF, Chisci E, Kutryb-Zajac B, Confalonieri S, Smolenski RT, Giovannoni R, Colombo N, Bianchi F, Cavallaro U. CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells. Stem Cell Reports 2018;10:1412-25. [PMID: 29551673 DOI: 10.1016/j.stemcr.2018.02.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
2 Song Y, Pan Y, Liu J. The relevance between the immune response-related gene module and clinical traits in head and neck squamous cell carcinoma. Cancer Manag Res 2019;11:7455-72. [PMID: 31496804 DOI: 10.2147/CMAR.S201177] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
3 Jiang T, Xu X, Qiao M, Li X, Zhao C, Zhou F, Gao G, Wu F, Chen X, Su C, Ren S, Zhai C, Zhou C. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers. BMC Cancer 2018;18:267. [PMID: 29514610 DOI: 10.1186/s12885-018-4073-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 11.5] [Reference Citation Analysis]
4 Petruk N, Tuominen S, Åkerfelt M, Mattsson J, Sandholm J, Nees M, Yegutkin GG, Jukkola A, Tuomela J, Selander KS. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer. Sci Rep 2021;11:6035. [PMID: 33727591 DOI: 10.1038/s41598-021-85379-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Maino Vieytes CA, Rodriguez-Zas SL, Madak-Erdogan Z, Smith RL, Zarins KR, Wolf GT, Rozek LS, Mondul AM, Arthur AE. Adherence to a priori-Defined Diet Quality Indices Throughout the Early Disease Course Is Associated With Survival in Head and Neck Cancer Survivors: An Application Involving Marginal Structural Models. Front Nutr 2022;9:791141. [PMID: 35548563 DOI: 10.3389/fnut.2022.791141] [Reference Citation Analysis]
6 Xiong D, Wu W, Kan L, Chen D, Dou X, Ji X, Wang M, Zong Z, Li J, Zhang X. LINC00958 and HOXC13-AS as key candidate biomarkers in head and neck squamous cell carcinoma by integrated bioinformatics analysis. PeerJ 2020;8:e8557. [PMID: 32095369 DOI: 10.7717/peerj.8557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 de Leve S, Wirsdörfer F, Jendrossek V. The CD73/Ado System-A New Player in RT Induced Adverse Late Effects. Cancers (Basel) 2019;11:E1578. [PMID: 31623231 DOI: 10.3390/cancers11101578] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wang G, Fu S, Li D, Chen Y. Expression and clinical significance of serum NT5E protein in patients with colorectal cancer. CBM 2019;24:461-8. [DOI: 10.3233/cbm-182207] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Panigrahi S, Bazdar DA, Albakri M, Ferrari B, Antonelli CJ, Freeman ML, Dubyak G, Zender C, Sieg SF. CD8+ CD73+ T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue. Eur J Immunol 2020;50:2055-66. [PMID: 32548862 DOI: 10.1002/eji.202048626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Wilkat M, Bast H, Drees R, Dünser J, Mahr A, Azoitei N, Marienfeld R, Frank F, Brhel M, Ushmorov A, Greve J, Goldberg-Bockhorn E, Theodoraki MN, Doescher J, Laban S, Schuler PJ, Hoffmann TK, Brunner C. Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cells. Int J Cancer 2020;147:202-17. [PMID: 31846065 DOI: 10.1002/ijc.32835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zhang C, Qiao H, Guo W, Liu Y, Yang L, Liu Y, Jin B, Fu M, Wang G, Li W. CD100-plexin-B1 induces epithelial-mesenchymal transition of head and neck squamous cell carcinoma and promotes metastasis. Cancer Lett 2019;455:1-13. [PMID: 30981760 DOI: 10.1016/j.canlet.2019.04.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
12 Miyazaki M, Aoki M, Okado Y, Koga K, Hamasaki M, Nakagawa T, Sakata T, Nabeshima K. Highly expressed tumoral emmprin and stromal CD73 predict a poor prognosis for external auditory canal carcinoma. Cancer Sci 2020;111:3045-56. [PMID: 32473077 DOI: 10.1111/cas.14508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 2017;14:717-34. [PMID: 28741618 DOI: 10.1038/nrclinonc.2017.101] [Cited by in Crossref: 683] [Cited by in F6Publishing: 675] [Article Influence: 136.6] [Reference Citation Analysis]
14 Brauneck F, Haag F, Woost R, Wildner N, Tolosa E, Rissiek A, Vohwinkel G, Wellbrock J, Bokemeyer C, Schulze Zur Wiesch J, Ackermann C, Fiedler W. Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML. Oncoimmunology 2021;10:1930391. [PMID: 34211801 DOI: 10.1080/2162402X.2021.1930391] [Reference Citation Analysis]
15 Vijayan D, Smyth MJ, Teng MWL. Purinergic Receptors: Novel Targets for Cancer Immunotherapy. In: Zitvogel L, Kroemer G, editors. Oncoimmunology. Cham: Springer International Publishing; 2018. pp. 115-41. [DOI: 10.1007/978-3-319-62431-0_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Hu S, Meng F, Yin X, Cao C, Zhang G. NT5E is associated with unfavorable prognosis and regulates cell proliferation and motility in gastric cancer. Biosci Rep 2019;39:BSR20190101. [PMID: 30992388 DOI: 10.1042/BSR20190101] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
17 Sek K, Mølck C, Stewart GD, Kats L, Darcy PK, Beavis PA. Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. Int J Mol Sci 2018;19:E3837. [PMID: 30513816 DOI: 10.3390/ijms19123837] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 17.3] [Reference Citation Analysis]
18 Aoki M, Koga K, Miyazaki M, Hamasaki M, Koshikawa N, Oyama M, Kozuka-Hata H, Seiki M, Toole BP, Nabeshima K. CD73 complexes with emmprin to regulate MMP-2 production from co-cultured sarcoma cells and fibroblasts. BMC Cancer 2019;19:912. [PMID: 31510956 DOI: 10.1186/s12885-019-6127-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Turiello R, Pinto A, Morello S. CD73: A Promising Biomarker in Cancer Patients. Front Pharmacol 2020;11:609931. [PMID: 33364969 DOI: 10.3389/fphar.2020.609931] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Tsiampali J, Neumann S, Giesen B, Koch K, Maciaczyk D, Janiak C, Hänggi D, Maciaczyk J. Enzymatic Activity of CD73 Modulates Invasion of Gliomas via Epithelial-Mesenchymal Transition-Like Reprogramming. Pharmaceuticals (Basel) 2020;13:E378. [PMID: 33187081 DOI: 10.3390/ph13110378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kirches E, Steffen T, Waldt N, Hebert E, Pachow D, Wilisch-neumann A, Keilhoff G, Schneider T, Braunsdorf WEK, Warnke J, Mawrin C. The expression of the MSC-marker CD73 and of NF2/Merlin are correlated in meningiomas. J Neurooncol 2018;138:251-9. [DOI: 10.1007/s11060-018-2807-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Safarzadeh A, Alizadeh M, Beyranvand F, Falavand Jozaaee R, Hajiasgharzadeh K, Baghbanzadeh A, Derakhshani A, Argentiero A, Baradaran B, Silvestris N. Varied functions of immune checkpoints during cancer metastasis. Cancer Immunol Immunother 2021;70:569-88. [PMID: 32902664 DOI: 10.1007/s00262-020-02717-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:709-724. [PMID: 29059149 DOI: 10.1038/nrc.2017.86] [Cited by in Crossref: 250] [Cited by in F6Publishing: 233] [Article Influence: 50.0] [Reference Citation Analysis]
24 Sánchez-Melgar A, Muñoz-López S, Albasanz JL, Martín M. Antitumoral Action of Resveratrol Through Adenosinergic Signaling in C6 Glioma Cells. Front Neurosci 2021;15:702817. [PMID: 34539333 DOI: 10.3389/fnins.2021.702817] [Reference Citation Analysis]
25 Timperi E, Barnaba V. CD39 Regulation and Functions in T Cells. Int J Mol Sci 2021;22:8068. [PMID: 34360833 DOI: 10.3390/ijms22158068] [Reference Citation Analysis]
26 Yu J, Wang X, Lu Q, Wang J, Li L, Liao X, Zhu W, Lv L, Zhi X, Yu J, Jin Y, Zou Q, Ou Z, Liu X, Zhou P. Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway. Int J Cancer 2018;142:959-67. [PMID: 29047106 DOI: 10.1002/ijc.31112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
27 Campos-Contreras ADR, Díaz-Muñoz M, Vázquez-Cuevas FG. Purinergic Signaling in the Hallmarks of Cancer. Cells 2020;9:E1612. [PMID: 32635260 DOI: 10.3390/cells9071612] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
28 Arab S, Hadjati J. Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy. Immune Netw 2019;19:e23. [PMID: 31501711 DOI: 10.4110/in.2019.19.e23] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
29 Ren ZH, Gong ZJ, Wu HJ. Unit resection of buccal squamous cell carcinoma: Description of a new surgical technique. Oncotarget 2017;8:52420-31. [PMID: 28881740 DOI: 10.18632/oncotarget.14191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
30 Baghbani E, Noorolyai S, Shanehbandi D, Mokhtarzadeh A, Aghebati-Maleki L, Shahgoli VK, Brunetti O, Rahmani S, Shadbad MA, Baghbanzadeh A, Silvestris N, Baradaran B. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. Life Sci 2021;282:119826. [PMID: 34265363 DOI: 10.1016/j.lfs.2021.119826] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
31 Feng LL, Cai YQ, Zhu MC, Xing LJ, Wang X. The yin and yang functions of extracellular ATP and adenosine in tumor immunity. Cancer Cell Int 2020;20:110. [PMID: 32280302 DOI: 10.1186/s12935-020-01195-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
32 Galgaro BC, Beckenkamp LR, van den M Nunnenkamp M, Korb VG, Naasani LIS, Roszek K, Wink MR. The adenosinergic pathway in mesenchymal stem cell fate and functions. Med Res Rev 2021;41:2316-49. [PMID: 33645857 DOI: 10.1002/med.21796] [Reference Citation Analysis]
33 Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DHG, Dhungel B, Steel JC, Jayachandran A. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Front Oncol. 2018;8:269. [PMID: 30057891 DOI: 10.3389/fonc.2018.00269] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 9.5] [Reference Citation Analysis]
34 Deng WW, Li YC, Ma SR, Mao L, Yu GT, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma. Int J Cancer 2018;143:1494-504. [PMID: 29663369 DOI: 10.1002/ijc.31534] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
35 Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer 2018;6:57. [PMID: 29914571 DOI: 10.1186/s40425-018-0360-8] [Cited by in Crossref: 179] [Cited by in F6Publishing: 181] [Article Influence: 44.8] [Reference Citation Analysis]
36 Ramapriyan R, Caetano MS, Barsoumian HB, Mafra ACP, Zambalde EP, Menon H, Tsouko E, Welsh JW, Cortez MA. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther 2019;195:162-71. [PMID: 30439456 DOI: 10.1016/j.pharmthera.2018.11.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
37 Churov A, Zhulai G. Targeting adenosine and regulatory T cells in cancer immunotherapy. Hum Immunol 2021;82:270-8. [PMID: 33610376 DOI: 10.1016/j.humimm.2020.12.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Torres Á, Erices JI, Sanchez F, Ehrenfeld P, Turchi L, Virolle T, Uribe D, Niechi I, Spichiger C, Rocha JD, Ramirez M, Salazar-Onfray F, San Martín R, Quezada C. Extracellular adenosine promotes cell migration/invasion of Glioblastoma Stem-like Cells through A3 Adenosine Receptor activation under hypoxia. Cancer Lett 2019;446:112-22. [PMID: 30660649 DOI: 10.1016/j.canlet.2019.01.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
39 Ledinsky Opačić I, Gršić K, Šitić S, Penavić I, Pastorčić Grgić M, Šarčević B. POSITIVE EXPRESSION OF NEDD9 IN HEAD AND NECK CANCER IS RELATED TO BETTER SURVIVAL PERIOD. Acta Clin Croat 2019;58:655-61. [PMID: 32595251 DOI: 10.20471/acc.2019.58.04.13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Miserocchi G, Cocchi C, De Vita A, Liverani C, Spadazzi C, Calpona S, Di Menna G, Bassi M, Meccariello G, De Luca G, Campobassi A, Maddalena Tumedei M, Bongiovanni A, Fausti V, Cotelli F, Ibrahim T, Mercatali L. Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas. Cancer Biol Med 2021:j. [PMID: 33772505 DOI: 10.20892/j.issn.2095-3941.2020.0482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Zhao H, Liao X, Kang Y. Tregs: Where We Are and What Comes Next? Front Immunol 2017;8:1578. [PMID: 29225597 DOI: 10.3389/fimmu.2017.01578] [Cited by in Crossref: 105] [Cited by in F6Publishing: 100] [Article Influence: 21.0] [Reference Citation Analysis]
42 Iser IC, Vedovatto S, Oliveira FD, Beckenkamp LR, Lenz G, Wink MR. The crossroads of adenosinergic pathway and epithelial-mesenchymal plasticity in cancer. Semin Cancer Biol 2022:S1044-579X(22)00156-0. [PMID: 35779713 DOI: 10.1016/j.semcancer.2022.06.012] [Reference Citation Analysis]
43 Chen X, Song X, Li K, Zhang T. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. Front Immunol 2019;10:292. [PMID: 30863404 DOI: 10.3389/fimmu.2019.00292] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]